Skip to content

Effect of Ayurvedic herbal Cap In High Blood Pressure Patients

Randomized Controlled Clinical Study To Evaluate Add-On Effect of Polyherbal Ayurvedic Formulation (Cap.BPSolve) With Tab. Telmisartan In the Management Of Essential Hypertension - Nil

Status
Recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/01/101068
Enrollment
160
Registered
2026-01-14
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I10- Essential (primary) hypertension

Interventions

None listed

Sponsors

Amruta Chandrakant Pacharne
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Systolic Blood Pressure: less than 170 mm of Hg more than or equal to 140 mm of Hg. Diastolic Blood Pressure: less than or equal to 110 mm of Hg More than 90 mm of Hg. Patient willing to participate in the research & to sign the written informed consent form.

Exclusion criteria

Exclusion criteria: Patient who has past history of atrial fibrillation, acute coronam syndrome, myocardial infarction, stroke or right ventricular hypertrophy, left ventricular hypertrophy, severe arrhythmia months. Symptomatic patients with clinical features of early heart fai Secondary hypertension. Women who are pregnant and lactating or on estrogen rep therapy. Alcoholics and drug abusers. Accelerated and malignant hypertension.

Design outcomes

Primary

MeasureTime frame
To Assess Add-on effect of Polyherbal Ayurvedic Formulation (Cap.BPSolve) with Tab. Telmisartan on Systolic blood pressure (SBP), Diastolic blood pressure(DBP), Heart rate (HR) in reduction of Essential HypertensionTimepoint: 0th (baseline), 5 th , 10 th , 15 th day end of study with 5 days interval

Secondary

MeasureTime frame
To Assess Add-on effect of Polyherbal Ayurvedic Formulation (Cap.BPSolve) with Tab. Telmisartan on other parameters like Headache, Giddiness, Fatigue, Palpitation, Insomnia etc.Timepoint: 0th (baseline), 5 th , 10 th , 15 th day end of study with 5 days interval

Countries

India

Contacts

Public ContactDr Satish Digambar Urhe

Siddhakala Ayurveda Mahavidyalaya , Sangmaner

drsatishurhe9@gmail.com9890035901

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026